Estimating the Complier Average Causal Effect for Exponential Survival in the Presence of Mid-Trial Switching
DOI:
https://doi.org/10.6000/1929-6029.2012.01.02.01Keywords:
Complier average causal effect, clinical trial, exponential survival, intent-to-treat, all-or-none compliance, per-protocol, switchingAbstract
The intention-to-treat (ITT) rate ratio estimator is conservatively biased for the treatment effect among compliers (who stick with their assigned arm) when individuals switch treatment in two-arm randomised trials. In this article we propose simple ways to estimate the complier average causal effect (CACE) with mid-trial switching. The estimators use aggregate data of events and times rather than individualised data. The motivating model considers survival times as exponentially distributed conditional on whether the individual would comply with randomisation. To estimate the CACE the ante-switch treatment effect and the post-switch treatment effect amongst the compliers are combined. Furthermore, we discuss ways of estimating the counterfactual intent-to-treat (ITT) effect, which is defined as the rate ratio if switching was not permitted. This approach might be a useful alternative to CACE estimation, and so a time and event adjustment of the non-compliers data is developed. Finally, simulated switching scenarios are used to illustrate the importance of correcting for informative switching.
References
Little RJ, Long Q, Lin X. A comparison of methods for estimating the causal effect of a treatment in randomized clinical trials subject to noncompliance. Biometrics 2009; 65(2): 640-49. http://dx.doi.org/10.1111/j.1541-0420.2008.01066.x DOI: https://doi.org/10.1111/j.1541-0420.2008.01066.x
Yau LHY, Little RJ. Inference for the complier-average causal effect from longitudinal data subject to noncompliance and missing data, with application to a job training assessment for the unemployed. J Am Statist Assoc 2001; 96(456): 1232-44. http://dx.doi.org/10.1198/016214501753381887 DOI: https://doi.org/10.1198/016214501753381887
The BIG 1-98 Collaborative Group. Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer. N Engl J Med 2009; 361(8): 766-76. DOI: https://doi.org/10.1056/NEJMoa0810818
White IR. Estimating treatment effects in randomized trials with treatment switching. Statist Med 2006; 25(9): 1619-22. http://dx.doi.org/10.1002/sim.2453 DOI: https://doi.org/10.1002/sim.2453
White IR, Babiker AG, Walker S, Darbyshire JH. Randomization-based methods for correcting for treatment changes: examples from the Concorde trial. Statist Med 1999; 18(19): 2617-34. http://dx.doi.org/10.1002/(SICI)1097-0258(19991015)18:19<2617::AID-SIM187>3.0.CO;2-E DOI: https://doi.org/10.1002/(SICI)1097-0258(19991015)18:19<2617::AID-SIM187>3.0.CO;2-E
Shao J, Chang M, Chow SC. Statistical inference for cancer trials with treatment switching. Statist Med 2005; 24(12): 1783-90. http://dx.doi.org/10.1002/sim.2128 DOI: https://doi.org/10.1002/sim.2128
Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Statistics-Theory Methods 1991; 20(8): 2609-31. http://dx.doi.org/10.1080/03610929108830654 DOI: https://doi.org/10.1080/03610929108830654
Branson M, Whitehead J. Estimating a treatment effect in survival studies in which patients switch treatment. Statist Med 2002; 21(17): 2449-63. http://dx.doi.org/10.1002/sim.1219 DOI: https://doi.org/10.1002/sim.1219
White IR, Babiker AG, Walker S, Darbyshire JH. An approximate randomisation-respecting adjustment to the hazard ratio for time-dependent treatments switches in clinical trials, technical report 2004.
Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Statist Med 1997; 16(9): 1017-29. http://dx.doi.org/10.1002/(SICI)1097-0258(19970515)16:9<1017::AID-SIM508>3.0.CO;2-V DOI: https://doi.org/10.1002/(SICI)1097-0258(19970515)16:9<1017::AID-SIM508>3.0.CO;2-V
Sommer A, Zeger SL. On estimating efficacy from clinical trials. Statist Med 1991; 10(1): 45-52. http://dx.doi.org/10.1002/sim.4780100110 DOI: https://doi.org/10.1002/sim.4780100110
Duffy SW, Cuzick J, Tabar L, et al. Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes. J Royal Statist Soc Ser C (Appl Statist) 2002; 51(2): 235-43. http://dx.doi.org/10.1111/1467-9876.00266 DOI: https://doi.org/10.1111/1467-9876.00266
Kerkhof M, Roobol MJ, Cuzick J, et al. Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (erspc section rotterdam). Int J Cancer 2010; 127(11): 2639-44. http://dx.doi.org/10.1002/ijc.25278 DOI: https://doi.org/10.1002/ijc.25278
Cuzick J, Sasieni P, Myles J, Tyrer J. Estimating the effect of treatment in a proportional hazards model in the presence of non-compliance and contamination. J Royal Statist Soc: Ser B (Statist Methodol) 2007; 69(4): 565-88. http://dx.doi.org/10.1111/j.1467-9868.2007.00600.x DOI: https://doi.org/10.1111/j.1467-9868.2007.00600.x
Loeys T, Goetghebeur E. A Causal Proportional Hazards Estimator for the Effect of Treatment Actually Received in a Randomized Trial with All-or-Nothing Compliance. Biometrics 2003; 59(1): 100-105. http://dx.doi.org/10.1111/1541-0420.00012 DOI: https://doi.org/10.1111/1541-0420.00012
Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000; 56(3): 779-88. http://dx.doi.org/10.1111/j.0006-341X.2000.00779.x DOI: https://doi.org/10.1111/j.0006-341X.2000.00779.x
Anderson JR, Bernstein L. Asymptotically efficient two-step estimators of the hazards ratio for follow-up studies and survival data. Biometrics 1985; 733-39. http://dx.doi.org/10.2307/2531293 DOI: https://doi.org/10.2307/2531293
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2012 Zihua Yang, Adam R. Brentnall, Jack Cuzick, Peter Sasieni
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
